Capricor Therapeutics Sued for Deramiocel Misrepresentation Amid Class Action Lawsuit

Capricor Therapeutics Faces Class Action Over Deramiocel Misrepresentation

Capricor Therapeutics, Inc. finds itself embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP. The lawsuit targets alleged securities fraud linked to misleading statements concerning the company's lead cell therapy candidate, deramiocel, which aims to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The legal action covers a timeframe from October 9, 2024, to July 10, 2025, during which the defendants are accused of misrepresenting the potential acquisition of a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). The lawsuit alleges that the company failed to disclose critical adverse data from its Phase 2 HOPE-2 trial, leading to a misinformed investor base.

The situation escalates following the receipt of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denies the BLA due to insufficient evidence of effectiveness and other unresolved issues. This denial results in a sharp decline in Capricor's stock price, which drops from $11.40 to $7.64 per share. The lawsuit highlights the potential repercussions for the company, as investors who suffered losses during the specified period are now seeking to recover their investments. Those interested have until September 15, 2025, to apply for lead plaintiff status, although it is noted that participation in any recovery does not require this designation.

Levi & Korsinsky emphasizes that class members will incur no out-of-pocket costs related to the lawsuit. The firm boasts a robust track record in securities litigation, having secured substantial recoveries for shareholders over the last two decades. Their recognition in ISS Securities Class Action Services' Top 50 Report for seven consecutive years further underscores their reputation in handling complex securities cases. As Capricor navigates these challenges, the outcome of this lawsuit could have significant implications not only for the company's financial standing but also for its credibility within the biotechnology field, particularly concerning its ongoing research and development efforts.

In other industry news, Biohaven Ltd. (BHVN) experiences a surge in its stock price following an update on its New Drug Application (NDA) for troriluzole, a treatment for adult patients with Spinocerebellar Ataxia (SCA). This positive momentum signals growing investor confidence in the company's regulatory progress and its commitment to addressing unmet medical needs in rare neurological disorders. As the pharmaceutical landscape evolves, Capricor's current legal struggles contrast sharply with Biohaven's optimistic trajectory, highlighting the high stakes involved in drug development and market approval processes.